This Company has achieved a noteworthy series of important...

This Company has achieved a noteworthy series of important patent grants.

So far in 2012

Our Axcess III oral formulation technology now has the benefit of issued patent protection in all three of the largest pharmaceutical markets, the US, Europe, and Japan, as well as many other countries around the world.

We also announced patent grants for Axcess II in Japan and Korea, adding to the US and multiple other markets where this patent has issued.

And our Axcess IV patent, providing specific coverage for our oral parathyroid hormone program, also issued in two new important additional markets, Russia and Japan...


This is grossly under valued, the potential here is massive, it may take a while, most definitely worth holding.


In my opinion...